The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
Taiwan’s Ministry of Health and Welfare has approved ropeginterferon alfa-2b-njft (BESREMi) for adult patients with essential thrombocythemia, according to PharmaEssentia, the manufacturer of the drug.
In this SOHO Insider interview from the 2026 AACR Annual Meeting, John DiPersio, MD, PhD, president of the Society of Hematologic Oncology, shares what he believes the future of blood cancers hold and how AI platforms will contribute to future discoveries.
Andrew Kuykendall, MD, an associate member from Moffitt Cancer Center, discusses updated data from the phase 2 RALLY-MF trial. The trial evaluated DISC-0974 in patients with myelofibrosis and anemia. DISC-0974 is a first-in-class monoclonal antibody designed to block hemojuvelin.
In this video from the 2026 ASCO Annual Meeting, Dr. Mascarenhas, a Professor of Medicine at the Icahn School of Medicine at Mount Sinai, discusses results from the phase 3 SENTRY trial.
Your contributions fund vital programs that accelerate progress in hematologic malignancies. Visit soho.click/donate to join the initiative.
![Insider_YT_Feature_Pannunzio_CLFR2_400x400[15]](https://sohoinsider.com/wp-content/uploads/2026/06/Insider_YT_Feature_Pannunzio_CLFR2_400x40015.png)
Nicholas R. Pannunzio, PhD, of the University of California, Irvine and the Chao Family Comprehensive Cancer Center, discusses the underlying etiology of CRLF2-rearranged Ph-like acute lymphoblastic leukemia.
SOHO Insider is the official media platform of the Society of Hematologic Oncology. The SOHO Insider Editorial Board is comprised of leading hematologists. Learn more about our editorial board and SOHO Insider platforms.
To access the SOHO Career Center click the following link.
